Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial - 26/03/20
Doi : 10.1016/j.jaad.2020.02.005
Rachel G. Casseres, BA a, b, Lisa Prussick, BSc, MD a, b, Pedro Zancanaro, MD a, Brooke Rothstein, MD a, Deep Joshipura, MD a, Ami Saraiya, MD a, Yana Turkowski, MD a, Shiu Chung Au, MD a, Abdulaziz Alomran, MD a, Rana Abdat, MD a, Minawaer Abudu, MD a, Courtney Kachuk, RN a, Nicole Dumont a, Alice B. Gottlieb, MD, PhD c, David Rosmarin, MD a, ⁎ 
a Tufts Medical Center, Department of Dermatology, Boston, Massachusetts
b Tufts University School of Medicine, Boston, Massachusetts
c Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York
∗Correspondence to: David Rosmarin, MD, 800 Washington St, PO Box 114, Boston, MA 02111800 Washington StPO Box 114BostonMA02111
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Thursday 26 March 2020
| Funding sources: This study was financially supported by Novartis. Novartis was not involved in the collection, management, analysis, preparation, approval of the manuscript, or decision to submit the manuscript for publication. |
|
| Disclosure: Dr Rosmarin has received honoraria as a consultant for AbbVie, Celgene, Dermavant, Dermira, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and Sun Pharmaceuticals; has received research support from AbbVie, Bristol-Myers Squibb, Celgene, Dermira, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and has served as a paid speaker for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, and Sanofi. Dr Gottlieb has consulted for and received research grants from Novartis; has consulted for and served on the advisory board or speakers bureau for Janssen, Celgene, Bristol-Myers Squibb, Beiersdorf, AbbVie, UCB, Incyte, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries, XBiotech, Leo, Avotres, and Boehringer Ingelheim. She has also received educational or research grants from Incyte, XBiotech, Janssen, UCB, and Boehringer Ingelheim. Ms Casseres; Drs Prussick, Zancanaro, Rothstein, Joshipura, Saraiya, Turkowski, Chun Au, Alomran, Abdat, and Abudu; and Ms Kachuk have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the Tufts Health Sciences IRB. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?